Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Colonoscopy Versus Stool-based Testing for Older Adults With a History of Colon Polyps

NCT ID: NCT05612347Sponsor: Dartmouth-Hitchcock Medical CenterLast updated: 2026-05-07

Summary

This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.

Detailed description

Colon polyps are common among adults ≥50 years and people with colon polyps are recommended to undergo regular follow-up colonoscopy (surveillance) in hopes of preventing subsequent colorectal cancer (CRC). Older adults, particularly those who are age ≥70 years, most of whom have a history of only small colon polyps, may benefit little from repeated colonoscopies because of the increased risks of colonoscopy due to age and co-morbidities and potentially limited life expectancy due to other competing medical problems - CRC may never be a problem for them. Older adults may also be hesitant to get repeated colonoscopy because of the risk of complications (e.g., bleeding, perforation, etc.) and inconvenience. More surveillance options are needed to help address the concerns and challenges with repeated colonoscopies in older adults with a history of low-risk polyps. FIT is a noninvasive, stool-based test that is recommended and widely used in the US and globally for CRC screening in average-risk adults 45 to 75 years of age. In addition, FIT is already standard of care as a surveillance option for patients with a history of low-risk adenomas in Canada and has been shown to be equivalent to colonoscopy for screening of certain high-risk populations (e.g., those with a family history of CRC). However, FIT's role for surveillance among older adults who have a history of low-risk adenomas has not been studied in the US nor among older adults who may benefit from this noninvasive surveillance approach. The COOP Trial will fill this evidence gap and shed light on patient-, clinician-, and system-factors relevant to FIT for surveillance that together could potentially transform surveillance guidelines in the US and beyond The purpose of this study is to compare annual at-home stool-based testing, with a fecal immunochemical test (FIT), to colonoscopy in adults age 65-82 who have a history of colorectal polyps. The goal of the study is to compare how well FIT works compared to colonoscopy in looking for and finding colorectal cancer in older adults who have a history of colorectal polyps, as well as to understand people's experiences with using it compared to colonoscopy.

Arms & interventions

  • Diagnostic TestFIT

    Annual FIT

  • Diagnostic TestColonoscopy

    One time surveillance colonoscopy

Outcome measures

Primary

  • Incidence of advanced neoplasia in each study group, annual FIT and colonoscopy, assessed by comparing the detection of advanced neoplasia between the two study groups.

    The investigators will determine the incidence of advanced neoplasia, defined as adenocarcinoma of the colon or rectum or adenomas or serrated polyps ≥1 cm in size or with villous features or any dysplasia, or traditional serrated polyps, in both study groups through annual surveys asking about any changes in polyp history or new cancer diagnosis for up to 6 years and medical record review for up to 11 years. The incidence of advanced neoplasia will be compared between the two study group cumulatively after all the data has been collected.

    Time frame: Up to 11 years

Secondary

  • Change from baseline Satisfaction and Trust of colorectal screening testing assessed by Tiro et al (2005) Response Efficacy sub-scale from the general colorectal cancer screening survey.

    Time frame: Baseline, 1 year after surveillance colonoscopy, annually after each completed FIT for up to 6 years

  • Change from baseline worry about colorectal Cancer assessed by the Cancer Worry Scale (CWS)

    Time frame: Baseline and annually for up to 6 years

  • Change from baseline Perceived colorectal cancer susceptibility using Absolute perceived susceptibility to colorectal polyps subscale from McQueen (2010)

    Time frame: Baseline, annually for up to 6 years

  • Change from baseline Emotional benefit of surveillance assessed by a modified version of the Psychological Consequences Questionnaire (PCQ)

    Time frame: Baseline and annually for up to 6 years

  • Change from baseline perceived global health assessed by the Patient-Reported Outcomes Measurement Information System-Global 10

    Time frame: Baseline and annually for up to 6 years

  • Major and minor harms within 30 days of colonoscopy, as measured through chart review and telephone interview.

    Time frame: 30-45 days post colonoscopy for up to 6 years

Eligibility criteria

Sex: AllAge: 65 Years to 82 YearsHealthy volunteers: No
Inclusion Criteria: * English or Spanish speaking * Personal history of colorectal polyps * Most recent colonoscopy with ≤2 non-advanced polyps * Currently due or coming due within 12 months for colonoscopy * Able to provide written informed consent Exclusion Criteria: * Personal history of colorectal cancer * Personal history of genetic syndrome with high risk for colorectal cancer (e.g. Lynch Syndrome, Familial Adenomatous Polyposis Syndrome (FAP), or Serrated Polyposis Syndrome) * Personal history of inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease) * Most recent colonoscopy with advanced polyp(s) or ≥3 non-advanced polyps * Patients unlikely to benefit from polyp surveillance (e.g., history of heart disease or coronary artery disease with treatment in the last 6 months, heart failure affecting function, lung disease requiring use of home oxygen, stroke within the last 4 months, dementia affecting activities of daily living (ADL) or instrumental activities of daily living (IADL), severe liver disease requiring the use of certain medications to control fluid, confusion, or bleeding, severe kidney disease requiring dialysis, or a new cancer diagnosis within the last year) * Patients unable to provide written informed consent

Study locations (18)

University of Alabama Birmingham

Birmingham, Alabama, 35233

Active Not Recruiting

University of Arizona

Tucson, Arizona, 85719

Recruiting
Joshua Melson, MD · Contact

Jennifer Moreno Department of Veterans Affairs Medical Cneter

San Diego, California, 92161

Recruiting
Dr. Samir Gupta · Contact

Kaiser Permanente Northern California

Walnut Creek, California, 94596

Recruiting
Jeffrey Lee, MD, MPH · Contact

University of Colorado

Aurora, Colorado, 80045

Recruiting
Swati Patel, MD, MS · Contact

MedStar Health

Washington D.C., District of Columbia, 20010

Recruiting
Jennifer Tran, MD · Principal Investigator

James A. Haley Veterans Hospital

Tampa, Florida, 33612-4745

Recruiting
Brijesh Patel, MD · Contact

Northwestern Memorial Hospital

Chicago, Illinois, 60611

Recruiting
Rajesh Keswani, MD · Principal Investigator

Richard L. Roudebush VA Medical Center

Indianapolis, Indiana, 46202

Recruiting
Thomas Imperiale, MD · Contact

University of Michigan Health

Ann Arbor, Michigan, 48105

Recruiting
Nabrah Lone · Contact
Stacy Menees, MD · Principal Investigator

Henry Ford

Detroit, Michigan, 48202

Recruiting
Dr. Suraj Suresh, MD · Contact

Dartmouth Health

Lebanon, New Hampshire, 03756

Recruiting
Audrey Calderwood, MD, MS · Contact

New York Harbor Health Care System - Dept of Veterans Affairs

New York, New York, 10010

Recruiting
Aasma Shaukat, MD · Contact

Kaiser Permanente Northwest

Portand, Oregon, 97232

Active Not Recruiting

Oregon Health & Science University (Knight Cancer Institute)

Portland, Oregon, 97239

Recruiting
Seth Crockett, MD, MPH · Contact

University of Utah

Salt Lake City, Utah, 84112

Recruiting
Andrew Gawron, MD · Contact
Lynette Holman · Contact

Intermountain Health

Sandy City, Utah, 84094

Recruiting
Dr. Christine Hachem, MD, FACG · Contact

University of Virginia Health

Charlottesville, Virginia, 22903

Recruiting
Cynthia Yoshida, MD · Contact

References

  • Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, Robertson DJ, Shaukat A, Syngal S, Rex DK. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020 Mar;158(4):1131-1153.e5. doi: 10.1053/j.gastro.2019.10.026. Epub 2020 Feb 7. No abstract available.(PubMed)
  • Dubé C, McCurdy BR, Bronstein T, et al. ColonCancerCheck Recommendations for Post-Polypectomy Surveillance, 2019. Available at: https://www.cancercareontario.ca/en/content/coloncancercheck-recommendations-post-polypectomy-surveillance
  • Quintero E, Carrillo M, Gimeno-Garcia AZ, Hernandez-Guerra M, Nicolas-Perez D, Alonso-Abreu I, Diez-Fuentes ML, Abraira V. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening. Gastroenterology. 2014 Nov;147(5):1021-30.e1; quiz e16-7. doi: 10.1053/j.gastro.2014.08.004. Epub 2014 Aug 13.(PubMed)
  • Kothari ST, Huang RJ, Shaukat A, Agrawal D, Buxbaum JL, Abbas Fehmi SM, Fishman DS, Gurudu SR, Khashab MA, Jamil LH, Jue TL, Law JK, Lee JK, Naveed M, Qumseya BJ, Sawhney MS, Thosani N, Yang J, DeWitt JM, Wani S; ASGE Standards of Practice Committee Chair. ASGE review of adverse events in colonoscopy. Gastrointest Endosc. 2019 Dec;90(6):863-876.e33. doi: 10.1016/j.gie.2019.07.033. Epub 2019 Sep 25.(PubMed)
  • Warren JL, Klabunde CN, Mariotto AB, Meekins A, Topor M, Brown ML, Ransohoff DF. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009 Jun 16;150(12):849-57, W152. doi: 10.7326/0003-4819-150-12-200906160-00008.(PubMed)
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps | Cancerify